Skip to content
Triangle logo TriangleGet started
← Study library

NCT00982111 · CITED IN SOURCE DOCUMENTS

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2022-01-11

The research study is testing the investigational drug necitumumab in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and pemetrexed will be more effective in improving participant disease than the standard chemotherapy combination alone.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Survival Time (OS)

→

outcome · POSTED

Progression-Free Survival (PFS)

→

outcome · POSTED

Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate [ORR])

→

outcome · POSTED

Time to Treatment Failure (TTF)

→

outcome · POSTED

Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab

→

outcome · POSTED

Number of Participants With Serum Anti-Necitumumab Antibody Assessment (Immunogenicity)

→

outcome · POSTED

Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimensions (EQ-5D)

→

outcome · POSTED

Mean Change From Baseline in PRO as Measured Using the Lung Cancer Symptom Scale (LCSS)

→

outcome · POSTED

Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC)

→

outcome · POSTED

Percentage of Participants With EGFR Measured by IHC

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Has histologically or cytologically confirmed nonsquamous (adenocarcinoma/large cell or other) non small cell lung cancer * Has Stage IV disease at the time of study entry * Measurable or nonmeasurable disease (as defined by the Response Evaluation Criteria in Solid Tumors RECIST 1.0) at the time of study entry (participants with only truly nonmeasurable disease are not eligible) * Has resolution to Grade ≤ 1 of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of alopecia) * Has an Eastern Cooperative Oncology Group performance status score of 0-2 * Has adequate hepatic function * Has adequate renal function * Has adequate hematologic function * If female, is surgically sterile, postmenopausal, or compliant with a highly effective contraceptive method during and for 6 months after the treatment period (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method). If male, the participants surgically sterile or compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period * Female participants of childbearing potential must have a negative serum Exclusion Criteria: * Has squamous non small cell lung cancer * Has received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the Epidermal Growth Factor Hormone (EGFR), vascular endothelial growth factor (VEGF), or VEGF receptor * Received previous chemotherapy for advanced NSCLC (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 1 year prior to randomization) * Undergone major surgery or received any investigational therapy in the 4 weeks prior to randomization * Undergone chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions, which is allowed) * Has brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants. Participants who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic and no longer require treatment with steroids or anticonvulsants, are eligible * Has superior vena cava syndrome contraindicating hydration * Has current clinically-relevant coronary artery disease or uncontrolled congestive heart failure * Has experienced myocardial infarction within 6 months prior to randomization * Has an ongoing or active infection (requiring antibiotics), including active tuberculosis or known infection with the human immunodeficiency virus * Has a history of significant neurological or psychiatric disorders, including dementia, seizures, or bipolar disorder, potentially precluding protocol compliance * Has Grade ≥ 2 peripheral neuropathy * Has significant third space fluid retention, requiring repeated drainage * Has any other serious uncontrolled medical disorders or psychological conditions that would, in the opinion of the investigator, limit the participant's ability to complete the study or sign an informed consent document The participant has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of IMC-11F8, or any other contraindication to one of the administered treatments * Is pregnant or breastfeeding * Has a known history of drug abuse * Has a concurrent active malignancy other than adequately-treated basal cell carcinoma of the skin or preinvasive carcinoma of the cervix. A participant with previous history of malignancy other than NSCLC is eligible, provided that he/she has been free of disease for ≥ 3 years
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Necitumumab + Pemetrexed + Cisplatin
    intervention Names
    1. Drug: Pemetrexed
    2. Drug: Cisplatin
    3. Biological: Necitumumab
    label
    Necitumumab + Pemetrexed + Cisplatin
    type
    EXPERIMENTAL
  2. description
    Pemetrexed + Cisplatin
    intervention Names
    1. Drug: Pemetrexed
    2. Drug: Cisplatin
    label
    Pemetrexed + Cisplatin
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Necitumumab + Pemetrexed + Cisplatin
    2. Pemetrexed + Cisplatin
    description
    500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
    name
    Pemetrexed
    other Names
    1. Alimta®
    2. LY231514
    type
    DRUG
  2. arm Group Labels
    1. Necitumumab + Pemetrexed + Cisplatin
    2. Pemetrexed + Cisplatin
    description
    75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
    name
    Cisplatin
    type
    DRUG
  3. arm Group Labels
    1. Necitumumab + Pemetrexed + Cisplatin
    description
    800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
    name
    Necitumumab
    other Names
    1. IMC-11F8
    2. LY3012211
    3. Portrazza®
    type
    BIOLOGICAL
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
633
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    OS is defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive. OS was estimated using the Kaplan-Meier method.
    measure
    Overall Survival Time (OS)
    time Frame
    Randomization to Death from Any Cause (Up to 31.6 Months)
secondary Outcomes
  1. description
    PFS is defined as the time from randomization until the first radiographic documentation of measured progressive disease as defined by RECIST (Version 1.0), or death from any cause. Participants who die without a reported prior progression will be considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. If no baseline or postbaseline radiologic assessment was available, the participant was censored at the date of randomization. If death or PD occurs after two or more consecutive missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits.
    measure
    Progression-Free Survival (PFS)
    time Frame
    Randomization to Measured Progressive Disease or Death from Any Cause (Up to 30.4 Months)
  2. description
    ORR is confirmed best overall tumor response of CR or PR. According to RECIST v1.0, CR was defined as the disappearance of all target and non-target lesions; PR defined as a \>30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD. Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence)/total number of participants treated) \* 100.
    measure
    Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate [ORR])
    time Frame
    Baseline to Measured Progressive Disease (Up to 30.4 Months)
  3. description
    TTF was defined as the time from study enrollment/randomization to the first observation of measured progressive disease, death from any cause, or early discontinuation of treatment or initiation of new anti-cancer therapies. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Progressive Disease (PD) was defined as having at least a 20% increase in sum of longest diameter of target lesions. Time to treatment failure was censored at the date of the last follow-up visit for participants who did not discontinue early, who were still alive, and who have not progressed.
    measure
    Time to Treatment Failure (TTF)
    time Frame
    Randomization to Measured Progressive Disease, Death from Any Cause, Discontinuation of Treatment or Initiation of New Anticancer Therapy (Up to 30.4 Months)
  4. measure
    Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab
    time Frame
    Predose Day 1 of Cycle 2,3,4,5 and 6 Prior to Necitumumab Infusion, Up to 23 Weeks
  5. description
    A participant was considered to have an anti-Necitumumab antibody response if anti-drug antibodies (ADA) were confirmed positive. Treatment emergent antibodies were defined as any anti-Necitumumab antibody titer equal to or greater than 4-fold the participant's baseline titer.
    measure
    Number of Participants With Serum Anti-Necitumumab Antibody Assessment (Immunogenicity)
    time Frame
    Baseline to Study Completion (Up to 31.6 Months)
  6. description
    The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a three level scale 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).
    measure
    Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimensions (EQ-5D)
    time Frame
    Baseline, Cycle 6 (Cycle = 3 weeks)
  7. description
    The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\] and 3 items were global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-mm lines. A higher score for any item represented a higher level of symptoms/problems. Scores for each of the reported categories ranged from 0 (for best outcome) to 100 (for worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom items of the LCSS, and the Total LCSS was the mean of all 9 LCSS items. ASBI and Total LCSS were not computed for a participant if he/she had 1 or more missing values for the 6 and 9 items, respectively.
    measure
    Mean Change From Baseline in PRO as Measured Using the Lung Cancer Symptom Scale (LCSS)
    time Frame
    Baseline, Cycle 6 (Cycle =3 Weeks)
  8. description
    EGFR IHC H-score = weighted sum of % 1+ cells, twice % 2+ cells, and three times % 3+ cells. IHC H-score criteria assesses participants with a low EGFR expression defined by a H-score cutoff value of \< 200 and participants with a high EGFR expression defined by a H-score of cutoff value of \>=200.
    measure
    Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC)
    time Frame
    Baseline
  9. description
    EGFR IHC H-score = weighted sum of % 1+ cells, twice % 2+ cells, and three times % 3+ cells. IHC H-score criteria assesses participants with a low EGFR expression defined by a H-score cutoff value of \< 200 and participants with a high EGFR expression defined by a H-score of cutoff value of \>=200.
    measure
    Percentage of Participants With EGFR Measured by IHC
    time Frame
    Baseline
Full study description
brief Summary
The research study is testing the investigational drug necitumumab in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and pemetrexed will be more effective in improving participant disease than the standard chemotherapy combination alone.
detailed Description
Multinational, randomized, multicenter, open-label Phase 3 study of 633 participants with advanced, nonsquamous (Stage IV) NSCLC. Participants will be randomized on a 1:1 basis to receive first-line necitumumab plus chemotherapy consisting of pemetrexed and cisplatin in study Arm A, or first-line pemetrexed-cisplatin chemotherapy alone in Arm B. Baseline radiographic assessment of disease will be performed within 21 days prior to randomization (first treatment will be administered within 7 days following randomization). Participants will undergo radiographic assessment (computed tomography or magnetic resonance imaging) of disease status every 6 weeks (± 3 days), until there is radiographic documentation of progressive disease (PD). Chemotherapy will continue for a maximum of six cycles in each arm (Or until there is radiographic documentation of PD, toxicity requiring cessation, protocol noncompliance or withdrawal of consent); participants in Arm A only will continue to receive necitumumab until there is radiographic documentation of PD, toxicity requiring cessation, protocol noncompliance, or withdrawal of consent. After the end-of-study-visit (following PD), follow-up information regarding further anticancer treatment and survival will be collected every 2 months (± 7 days). For participants who discontinue study for reasons other than PD (eg, symptomatic deterioration), information on disease progression will also be collected until PD is documented. Follow-up will continue as long as the participant is alive, or until the end of the trial.
Source references
references
  1. citation
    Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa AE, Dediu M, Balint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA; INSPIRE investigators. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015 Mar;16(3):328-37. doi: 10.1016/S1470-2045(15)70046-X. Epub 2015 Feb 18.
    pmid
    25701171
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-4e71e42ebe6366c2182c
      requested nct id
      NCT00982111
      primary nct id
      NCT00982111
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
      payload sha256
      4efc2a673bf8af4cc3ac77e4c8e32d3fff6dcc984331cb24c06e209a3236e309
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-4e71e42ebe6366c2182c
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00982111
      occurrences
      1. context exact
        arm (72% vs. 62%). </li><li>Necitumumab is associated with higher toxicity and relatively modest benefit.</li></ul></div></li><li>The <a href="/clinicaltrials/NCT00982111">INSPIRE</a> trial (NCT00982111) randomly assigned 633 patients with advanced nonsquamous NSCLC to receive either first-line chemotherapy with cisplatin and p
        end
        471087
        exact text
        NCT00982111
        start
        471076
      2. context exact
        itumumab is associated with higher toxicity and relatively modest benefit.</li></ul></div></li><li>The <a href="/clinicaltrials/NCT00982111">INSPIRE</a> trial (NCT00982111) randomly assigned 633 patients with advanced nonsquamous NSCLC to receive either first-line chemotherapy with cisplatin and pemetrexed or to cisplatin and pe
        end
        471119
        exact text
        NCT00982111
        start
        471108
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/11a3437f29dc92742e.html
      source file sha256
      6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:59.782436+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      96af5062fe49c6481bdc1ef6946e69939f30c810b02e368845c837ccf6c0977c
      source title
      Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 15, 2025
        datetime
        2025-05-15T12:00:00Z
        display
        May 15, 2025

    Preserved source evidence · Not medical advice